AzTrials
AzTrials

IVMNCT06087354

Low vs. Air Oxygen Concentration CAPA-IVM Culture of Cumulus-oocyte Complexes

A study testing The way of Cumulus-oocyte complexes (COC) CAPA-IVM culture condition in people with IVM and PCOS (Polycystic Ovary Syndrome), run by Mỹ Đức Hospital at 1 site in Vietnam.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

IVM with a pre-maturation step, known as capacitation IVM (CAPA-IVM), has demonstrated enhanced maturation of human oocytes in vitro and successful live births. However, CAPA-IVM has shown lower rates of embryo formation when compared to conventional in vitro fertilization/ intra cytoplasmic sperm injection (IVF/ICSI)… Read more about this study

Who is it for?
Ages 18 to 37 years, women only
Conditions the study is for
IVM, PCOS (Polycystic Ovary Syndrome)
What is being tested?
The way of Cumulus-oocyte complexes (COC) CAPA-IVM culture condition
Could I receive a placebo?
No, everyone receives an active treatment
How many people
20 participants
Where
1 siteVietnam
Study dates
9 Nov 2023to 22 May 2024
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 37 years
  • Women only
  • No healthy volunteers
  • Adult

Who may be able to join

  • ≤38 years
  • Having polycystic ovarian morphology: at least 25 follicles (2-9 mm) throughout the whole ovary and/or increased ovarian volume (>10ml)
  • Having at least 20 follicles on the Oocyte Pick-up day
  • Patients consent to culture embryos to the blastocyst

Who cannot join

  • Cases with severe male factor (concentration <5 million/ml, cryptozoospermia, azoospermia)
  • Oocyte donation
  • Pre-implantation genetic testing

Trial locations and contacts

1 site in 1 country.

Vietnam1 site
  • My Duc Hospital

    Ho Chi Minh City, 70000

Other trials in Vietnam

About this study

Official title: Effect of Low Versus Air Oxygen Concentration in In-vitro Maturation With Biphasic Capacitation-IVM (CAPA-IVM) Culture of Human Cumulus-oocyte Complexes in PCOS Patients: a Sibling Oocyte Pilot Study

IVM with a pre-maturation step, known as capacitation IVM (CAPA-IVM), has demonstrated enhanced maturation of human oocytes in vitro and successful live births. However, CAPA-IVM has shown lower rates of embryo formation when compared to conventional in vitro fertilization/ intra cytoplasmic sperm injection (IVF/ICSI) cycles. To optimize the CAPA-IVM culture system, this pilot study aims to evaluate the impact of low oxygen versus air oxygen concentrations on embryological outcomes in PCOS patients.

Read the detailed description

Oocyte in vitro maturation (IVM) is an alternative approach to assisted reproductive technology (ART) that has the advantage of minimal stimulation, resulting in reduced hormone-related side effects and risks, especially in women with polycystic ovary syndrome (PCOS). Oocytes retrieved for IVM procedures are derived from a diverse pool of follicles with an average diameter of between 2 and 10mm and are characterized by variable cellular and molecular attributes that indicate their immature status. Therefore, the development of an IVM culture system that could enable and enhance the acquisition and synchronization of meiotic and developmental competence prior to the meiotic resumption is essential for optimizing human IVM protocols.

IVM with a pre-maturation step, known as capacitation IVM (CAPA-IVM), has been shown to improve the competence of human oocytes matured in vitro and result in live births. The pre-maturation culture of CAPA-IVM utilizes C-type natriuretic peptide (CNP), and maturation takes place in the presence of amphiregulin (AREG), both of which are physiological compounds that have been shown to prevent spontaneous meiotic resumption of oocytes (CNP) and enhance oocyte competence (AREG) during IVM.

To date, the results of pilot studies have shown that CAPA-IVM increases the rates of oocyte maturation, good-quality embryos on day 3 and good-quality blastocysts, resulting in a result, a higher embryo yield was obtained compared with standard IVM. Additionally, the reported cumulative live birth rate after use of CAPA-IVM, and its non-inferiority to the cumulative live birth rate with standard in vitro fertilization highlight the clinical utility and potential of this approach. Improvements in the culture system could make CAPA-IVM more effective, but these need to be investigated.

The oxygen concentration during the IVM process plays a crucial role in oocyte maturation. The use of oxygen concentrations higher than physiological levels can lead to cell damage and affect embryo development. Recent studies in mice have suggested using lower oxygen concentrations to improve IVM outcomes. However, the effectiveness of using lower oxygen concentrations in human IVM remains unproven. Therefore, this pilot study aims to compare the effectiveness of lower oxygen concentration conditions versus air oxygen in CAPA-IVM on embryology outcomes in PCOS women.

Being tested
The way of Cumulus-oocyte complexes (COC) CAPA-IVM culture condition
Keywords
Low oxygen, CAPA-IVM, Cumulus-oocyte complexes
Medical subject headings
Polycystic Ovary Syndrome

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • The way of Cumulus-oocyte complexes (COC) CAPA-IVM culture conditionOther

    Cumulus-oocyte complexes (COC) will be cultured in CAPA-IVM 24 hrs capacitation followed by 30h maturation. The first group will be cultured in low oxygen concentration (5%Oxygen), 6% carbon dioxide at 37 degree. The second group will be cultured in air oxygen concentration (20%Oxygen), 6% carbon dioxide at 37 degree.

Study groups in NCT06087354
Study groupRoleWhat they receive
Low Oxygen Concentration CAPA-IVM cultureExperimentalHalf of COCs were cultured in the CAPA step and IVM step in a low oxygen concentration (5%) and 6% carbon dioxide at 37 degree
Receives: Other: The way of Cumulus-oocyte complexes (COC) CAPA-IVM culture condition
Air Oxygen Concentration CAPA-IVM cultureExperimentalHalf of COCs were cultured in the CAPA step and IVM step in a air oxygen concentration (20%) and 6% carbon dioxide at 37 degree
Receives: Other: The way of Cumulus-oocyte complexes (COC) CAPA-IVM culture condition

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Number of blastocyst

    Number of blastocyst obtained

    Measured: At least 5 days after intra-cytoplasmic sperm injection

Secondary outcomes (12)
  1. Number of matured oocytes

    Number of oocytes which have a polar body after maturation

    Measured: Two days after oocytes pick-up

  2. Number of normal fertilized oocytes

    Number of oocytes which have 2 pronuclear

    Measured: 16-18 hours after intra-cytoplasmic sperm injection

  3. Number of day-3 embryos

    Number of day-3 embryos obtained

    Measured: At least 3 days after intra-cytoplasmic sperm injection

  4. Number of good-quality day-3 embryos

    Number of good quality Day 3 embryos obtained

    Measured: At least 3 days after intra-cytoplasmic sperm injection

  5. Number of good-quality blastocyst

    Number of good quality blastocyst obtained

    Measured: At least 5 days after intra-cytoplasmic sperm injection

  6. Number of vitrified blastocyst

    Number of vitrified blastocyst obtained

    Measured: At least 5 days after intra-cytoplasmic sperm injection

  7. Positive pregnancy test

    Serum human chorionic gonadotropin level greater than 25 mIU/mL

    Measured: At 2 weeks after the completion of the first frozen embryo transfer

  8. Clinical pregnancy

    At least one gestational sac on ultrasound at 7 weeks' gestation with the detection of heart beat activity

    Measured: 5 weeks after embryo placement after the completion of the first transfer

  9. Ongoing pregnancy

    Defined as pregnancy with detectable heart rate at 12 weeks' gestation or beyond, after the completion of the first transfer

    Measured: At 12 weeks' gestation

  10. Implantation rate

    Defined as the number of gestational sacs per number of embryos transferred

    Measured: 3 weeks after embryo transferred after the completion of the first transfer

  11. Multiple pregnancy

    Defined as presence of more than one sac at early pregnancy ultrasound (6-8 weeks gestation)

    Measured: 5 weeks after embryo placement after the completion of the first transfer

  12. Miscarriage

    pregnancy loss at <12 weeks

    Measured: at 12 weeks of gestation after the completion of the first transfer

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted17 Oct 2023
  2. Study start9 Nov 2023
  3. Primary completion30 Jan 2024
  4. Study completion22 May 2024

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Non-randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
20 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06087354
Sponsor's protocol ID
11/23/DD-BVMD
Status last verified
Oct 2023
First submitted
12 Oct 2023
Last updated
3 Jun 2024
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Sanchez F, Le AH, Ho VNA, Romero S, Van Ranst H, De Vos M, Gilchrist RB, Ho TM, Vuong LN, Smitz J. Biphasic in vitro maturation (CAPA-IVM) specifically improves the developmental capacity of oocytes from small antral follicles. J Assist Reprod Genet. 2019 Oct;36(10):2135-2144. doi: 10.1007/s10815-019-01551-5. Epub 2019 Aug 9.

    PubMed 31399916
  • Vuong LN, Ho VNA, Ho TM, Dang VQ, Phung TH, Giang NH, Le AH, Pham TD, Wang R, Smitz J, Gilchrist RB, Norman RJ, Mol BW. In-vitro maturation of oocytes versus conventional IVF in women with infertility and a high antral follicle count: a randomized non-inferiority controlled trial. Hum Reprod. 2020 Nov 1;35(11):2537-2547. doi: 10.1093/humrep/deaa240.

    PubMed 32974672
  • Vuong LN, Le AH, Ho VNA, Pham TD, Sanchez F, Romero S, De Vos M, Ho TM, Gilchrist RB, Smitz J. Live births after oocyte in vitro maturation with a prematuration step in women with polycystic ovary syndrome. J Assist Reprod Genet. 2020 Feb;37(2):347-357. doi: 10.1007/s10815-019-01677-6. Epub 2020 Jan 4.

    PubMed 31902102
  • Preis KA, Seidel GE Jr, Gardner DK. Reduced oxygen concentration improves the developmental competence of mouse oocytes following in vitro maturation. Mol Reprod Dev. 2007 Jul;74(7):893-903. doi: 10.1002/mrd.20655.

    PubMed 17192892
  • Akin N, Ates G, von Mengden L, Herta AC, Meriggioli C, Billooye K, Stocker WA, Ghesquiere B, Harrison CA, Cools W, Klamt F, Massie A, Smitz J, Anckaert E. Effects of lactate, super-GDF9, and low oxygen tension during bi-phasic in vitro maturation on the bioenergetic profiles of mouse cumulus-oocyte complexdagger. Biol Reprod. 2023 Oct 13;109(4):432-449. doi: 10.1093/biolre/ioad085.

    PubMed 37531262

Questions about this trial

What is this clinical trial studying?

A study testing The way of Cumulus-oocyte complexes (COC) CAPA-IVM culture condition in people with IVM and PCOS (Polycystic Ovary Syndrome), run by Mỹ Đức Hospital at 1 site in Vietnam.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 3 Jun 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Vietnam. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Number of blastocyst (time frame: At least 5 days after intra-cytoplasmic sperm injection). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06087354, which also lists 5 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Jun 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in